Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $190.15 and last traded at $190.15, with a volume of 717 shares changing hands. The stock had previously closed at $197.44.
Genmab A/S Stock Down 3.7 %
The firm has a market cap of $12.56 billion, a PE ratio of 18.28 and a beta of 1.04. The company has a 50-day simple moving average of $210.08 and a two-hundred day simple moving average of $234.92.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- High Flyers: 3 Natural Gas Stocks for March 2022
- How to Invest in Small Cap Stocks
- Roth IRA Calculator: Calculate Your Potential Returns
- These Are the Dividend Stocks Insiders Bought in January
- What Investors Need to Know to Beat the Market
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
